Neumora Therapeutics (NMRA) Change in Acquisitions & Divestments (2022 - 2024)

Neumora Therapeutics' Change in Acquisitions & Divestments history runs 3 years deep, the most recent figure standing at $36.6 million for Q1 2024.

• In Q1 2024, Change in Acquisitions & Divestments fell 17.5% year-over-year to $36.6 million; the TTM figure through Mar 2024 stood at $159.4 million (changed N/A YoY), while the FY2023 annual figure was $178.2 million, up 147.91% from the prior year.
• Change in Acquisitions & Divestments for Q1 2024 stood at $36.6 million, down from $38.4 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $44.3 million in Q1 2023, with the low at $36.6 million in Q1 2024.
• The 3-year median for Change in Acquisitions & Divestments is $39.2 million (2022), against an average of $39.8 million.
• The sharpest annual moves came in 2023 and 2024: Change in Acquisitions & Divestments fell 4.25% in 2023, then retreated 17.5% in 2024.
• Neumora Therapeutics' Change in Acquisitions & Divestments stood at $40.1 million in 2022, then retreated by 4.25% to $38.4 million in 2023, then decreased by 4.7% to $36.6 million in 2024.
• Business Quant data shows NMRA's Change in Acquisitions & Divestments at $36.6 million in Q1 2024, $38.4 million in Q4 2023, and $44.3 million in Q1 2023.